Erica Friedman • May 14, 2025
Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Trial Studies Aficamten in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a Phase 3 clinical trial comparing aficamten as monotherapy to the standard of care beta blocker metoprolol as monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

MAPLE-HCM met its primary endpoint, demonstrating a statistically significant improvement in peak oxygen uptake (pVO2) from baseline to Week 24 for aficamten compared to metoprolol. The safety and tolerability profile of aficamten was favorable in comparison to metoprolol in MAPLE-HCM.

The full results from MAPLE-HCM will be presented at an upcoming medical conference.


Read More


HCMA Blog

A mixed race family in denim walks down a road, the child on a tricycle

June's Topic is Staying Fit With HCM

By Sabrina Cuddy • June 4, 2025
Experts agree that exercise is healthy for people with HCM. Depending on symptoms, most people with HCM can safely do at least light exercise. Learn more in this month's blog pog post by Health Educator Sabrina Cuddy.

Legislative Advocacy Updates June 2025

By Julie Russo • June 4, 2025
Nevada Adopts Component of Children's Cardiac Safety Bill introduced by HCMA Legislative Advocate Jane Grossman
A Caucasian hand with a pen rests on a clipboard that holds paper with writing.

Decisions in HCM: Where do Risk Estimates Come From?

By Gordon Fox • May 14, 2025
In the third of a series about decision-making and risk in HCM, Gordon Fox explains where risk data comes from and how to understand it.
More Posts